Establishment Labs (ESTA) Expected to Announce Earnings on Thursday

Establishment Labs (NASDAQ:ESTA) is expected to be issuing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Establishment Labs to announce earnings of ($0.3368) per share and revenue of $65.7910 million for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:30 AM ET.

Establishment Labs (NASDAQ:ESTA) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.10). The firm had revenue of $59.88 million during the quarter, compared to analysts’ expectations of $57.40 million. Establishment Labs had a negative return on equity of 218.77% and a negative net margin of 19.05%.The company’s quarterly revenue was up 44.7% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.70) earnings per share. On average, analysts expect Establishment Labs to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Establishment Labs Stock Performance

Establishment Labs stock opened at $92.80 on Tuesday. The firm’s 50 day simple moving average is $85.34 and its 200 day simple moving average is $73.77. The company has a current ratio of 2.96, a quick ratio of 1.91 and a debt-to-equity ratio of 16.82. The firm has a market capitalization of $2.73 billion, a PE ratio of -62.28 and a beta of 1.07. Establishment Labs has a 1-year low of $33.35 and a 1-year high of $97.59.

Insider Activity

In other news, Director Quiros Juan Jose Chacon sold 105,000 shares of Establishment Labs stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $75.42, for a total transaction of $7,919,100.00. Following the completion of the sale, the director directly owned 927,504 shares of the company’s stock, valued at approximately $69,952,351.68. The trade was a 10.17% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 9.99% of the company’s stock.

Institutional Investors Weigh In On Establishment Labs

Large investors have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. lifted its holdings in shares of Establishment Labs by 117.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 811,536 shares of the company’s stock worth $59,145,000 after acquiring an additional 438,206 shares during the last quarter. Viking Global Investors LP bought a new position in shares of Establishment Labs during the 2nd quarter valued at $14,669,000. Soleus Capital Management L.P. bought a new position in shares of Establishment Labs during the 2nd quarter valued at $9,050,000. Summit Partners Public Asset Management LLC raised its position in Establishment Labs by 87.1% in the 3rd quarter. Summit Partners Public Asset Management LLC now owns 430,160 shares of the company’s stock worth $17,632,000 after purchasing an additional 200,255 shares during the period. Finally, Nantahala Capital Management LLC raised its position in Establishment Labs by 11.1% in the 3rd quarter. Nantahala Capital Management LLC now owns 1,973,492 shares of the company’s stock worth $80,893,000 after purchasing an additional 197,962 shares during the period. Hedge funds and other institutional investors own 72.91% of the company’s stock.

Analysts Set New Price Targets

ESTA has been the subject of a number of recent analyst reports. TD Cowen boosted their price target on shares of Establishment Labs from $95.00 to $117.00 and gave the company a “buy” rating in a research report on Monday. Citigroup increased their price objective on Establishment Labs from $76.00 to $92.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 8th. Mizuho boosted their target price on Establishment Labs from $100.00 to $105.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 15th. BTIG Research restated a “buy” rating on shares of Establishment Labs in a research note on Monday, July 13th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Establishment Labs in a report on Wednesday, June 24th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $93.75.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.